Compassionate use of gc5131 (Hyperimmunoglobulin) therapy in critically ill patients diagnosed with covid-19: A case series and review of literature

Sunha Choi, Soyoon Hwang, Kitae Kwon

Research output: Contribution to journalArticlepeer-review


Presently, the use of convalescent plasma and hyperimmunoglobulin obtained from individuals who have recovered from coronavirus disease 2019 (COVID-19) has proved to potentially provide passive antibody-based immunity, thereby leading to several clinical trials to develop an immune-based COVID-19 treatment. However, the therapeutic efficacy of hyperimmunoglobulin in critically ill patients with COVID-19 remains unknown. On 23 October 2020, we first administered GC5131 in a compassionate-use program to critically ill patients at the Kyungpook National Univer-sity, Chilgok Hospital, Korea. Since then, five more critically ill patients were treated with GC5131 in this compassionate-use program in our hospital up until 17 December 2020. We retrospectively reviewed the clinical responses of six critically ill patients diagnosed with COVID-19 who received the hyperimmunoglobulin concentrate, GC5131, which was produced by the Green Cross Corpo-ration. After the administration of GC5131, five patients died due to an exacerbation of COVID-19 pneumonia. GC5131 was ineffective when administered to critically ill patients with COVID-19. Nevertheless, we propose that to expect a therapeutic effect from GC5131, it should be administered as early as possible to avoid the excessive inflammatory response phase in patients with severe and advanced COVID-19 infection. This step was difficult to achieve in the real world due to the time required for decision making and the process of the compassionate-use program.

Original languageEnglish
Article number1826
Issue number9
StatePublished - Sep 2021


  • COVID-19
  • Clinical effectiveness
  • Convalescence
  • Immunoglobulin
  • Plasma


Dive into the research topics of 'Compassionate use of gc5131 (Hyperimmunoglobulin) therapy in critically ill patients diagnosed with covid-19: A case series and review of literature'. Together they form a unique fingerprint.

Cite this